Better Therapeutics, Inc. (NASDAQ:BTTX) Q3 2023 Earnings Call Transcript

Frank Karbe: Yes, thanks for that question, Raul. So this is the guide you’re referring to, right, that opens up the possibility of expanding drug labeling to include the increased benefits patients may experience by also using a prescription digital therapy. And we think that has a number of benefits. If we strengthen drug labeling, it has potentially raised awareness about the concurrent benefits that PDTs can provide alongside pharmacotherapies, and that, of course, enables providers to improve clinical outcomes. And this differentiation in the label may be particularly relevant in, let’s say, the GLP-1 market. It’s a massive market with a lot of competition in this category. And we have a data set that we have announced publicly a few weeks ago that shows the added benefits that AspyreRx can provide when combined with standard of care, including GLP-1.

And we think that offers an opportunity to differentiate labels in this highly competitive marketplace, and we think this provides a basis for having some productive discussions with some of the physical players in this space.

Rahul Rakhit: Got it. That’s helpful. Yes, I guess I was wondering with the full select data set coming up later this weekend, questions around whether payers are going to be strict on covering GLP-1s or not, also just what’s the longevity of the impact of those drugs are without sustainable behavioral modifications. If there’s some urgency or — and the large opportunity for you guys to come and serve yourselves there?

Frank Karbe: Yes, I think there’s a number of benefits to just go beyond just what we talked about, maybe differentiating the label. I think the key benefit ultimately is to provide better clinical outcomes, and that can come through a variety of different ways. I think it is well known that many patients do not fully achieve the therapeutic dose of the GLP-1 that they’re on. We might be able to help with that. And keep in mind, when you combine a pharmaceutical drug with a PDT, there’s not only maybe the benefit that, let’s say, the behavioral therapy can provide, there’s also the benefit that the product itself can provide, for example, in maybe supporting medications hearing. So there’s a number of things that ultimately we believe have the potential to generate better clinical outcomes than other products below.

Rahul Rakhit: Awesome. Make that. Thank you.

Operator: Ladies and gentlemen, there are no further questions at this time. Thank you for participating in today’s conference. This concludes the program. You may now disconnect and have a wonderful day.